RxDoctor Payments Data

Kellie Spector, MD

Hematology & Oncology · Orange, CANPI 1700374469

Payments from drug & device makers

$11,018in general payments, 2019–2025

Across 291 payments — averaging $37.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Seagen Inc.$1K
  • AstraZeneca$655
  • Daiichi Sankyo Inc.$493
  • Incyte Corporation$463
  • Regeneron Healthcare Solutions, Inc.$447
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,08810%
  • Food & beverage$9,16683%
  • Education$7657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$1,154
Seagen Inc.15$1,082
AstraZeneca(2 entities)19$655
Daiichi Sankyo Inc.14$493
Incyte Corporation18$463
Regeneron Healthcare Solutions, Inc.8$447
Johnson & Johnson10$441
Sanofi8$440
E.r. Squibb & Sons, L.L.C.20$344
Eisai Inc.11$344
Novartis12$324
Jazz Pharmaceuticals Inc.3$306
Beone Medicines USA, Inc.8$299
Pfizer8$264
Astellas Pharma US Inc5$252
Gilead6$251
Amgen4$244
Bristol Myers Squibb9$236
Janssen Scientific Affairs, LLC2$224
Merck8$210
Genentech USA, Inc.7$199
AbbVie7$176
Ipsen Biopharmaceuticals, Inc6$156
Sobi, Inc5$155
Beigene USA, Inc.4$123
Lilly USA, LLC4$108
Genmab U.S., Inc.4$108
Stemline Therapeutics Inc.4$102
Array Biopharma Inc7$97
Bayer4$96
Karyopharm Therapeutics Inc.3$88
Puma Biotechnology, Inc.3$81
Boehringer Ingelheim2$79
Taiho Oncology, Inc.3$76
Sanofi-aventis U.S. LLC1$70
Mirati Therapeutics, Inc.3$62
GE HealthCare2$60
Springworks Therapeutics, Inc.2$55
Iovance Biotherapeutics, Inc.2$54
Coherus Oncology, Inc.2$54
Foundation Medicine, Inc.2$46
Rigel Pharmaceuticals, Inc.2$44
Exelixis Inc.1$38
EMD Serono, Inc.2$33
AVEO Pharmaceuticals, Inc.1$31
Caris MPI, Inc.1$29
Immunogen, Inc.1$29
Tersera Therapeutics LLC1$29
ADC Therapeutics America, Inc.1$28
Takeda Pharmaceuticals U.S.A., Inc.1$26
Kyowa Kirin, Inc.1$25
Fennec Pharmaceuticals, Inc.1$25
Verity Pharmaceuticals Inc.1$24
Deciphera Pharmaceuticals Inc.1$24
Sumitomo Pharma America, Inc.1$24
Helsinn Therapeutics (U.S.), Inc.1$18
Cumberland Pharmaceuticals, Inc.1$17
Tolmar, Inc.1$15
Pharmaessentia USA Corporation1$14
Myriad Genetic Laboratories, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,018 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$93,697
Medicare patients
74
Services billed
9,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole22$427
Pantoprazole Sodium11$21

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →